Device/Diagnostics Quarterly Deal Statistics, Q4 2012
A look at financing, M&A, and alliance activity, October – December 2012
Executive Summary
Device firms closed the final quarter of 2012 with $1.1 billion in financing, led by Volcano’s debt offering. Takeovers of Gambro and PSS Medical topped the device M&A list. At $196 million, Q4 diagnostic financing was the lowest quarter of the year, but IPOs returned with three public debuts. Amgen’s $415 million acquisition of deCODE was the largest diagnostic M&A.
You may also be interested in...
Baxter Acquires Gambro, Becomes Integrated Renal Therapy Leader
Baxter’s offer of $4 billion for Swedish hemodialysis manufacturer Gambro may be one of the largest medtech acquisitions of the year, but Baxter CEO Bob Parkinson describes the deal as a bolt-on for Baxter’s existing market in renal therapy. Of course the magnitude of the deal makes it “an adjacency with a capital A”, Parkinson quipped.
Renal Denervation Land Grab Continues As Boston Scientific Buys Vessix
In the latest of a series of deals in what many industry executives and analysts consider to be the next blockbuster device product market, Boston Scientific became the third major vascular player to buy its way into the renal denervation space with its recent acquisition of Vessix Vascular for a sum that could amount to $425 million. With this deal, Boston Scientific joins Medtronic, which led the way in 2010 with its stunning potentially billion dollar acquisition of Ardian, followed earlier this year by Covidien’s acquisition of Maya Medical.
MorphoSys Finds Right Time To Focus On Pipeline With AbD Serotec Sale To Bio-Rad Labs
MorphoSys sells some of its assets in an effort to concentrate on its proprietary therapeutic endeavors – including a mid-stage rheumatoid arthritis drug.